Moleculin Biotech Inc Stock News

Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript

Live webcast fireside chat on Monday, March 18 th at 9:00 AM PT HOUSTON , March 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmace

Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.

HOUSTON , Nov. 7, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinic

Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.

Moleculin Biotech (NASDAQ: MBRX ) stock is on the move Friday after the clinical-stage pharmaceutical company provided an update to investors. According to a press release from Moleculin Biotech, the

HOUSTON , Sept. 5, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clini

Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q2 2023 Earnings Call Transcript August 11, 2023 8:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman & CEO John Paul Waymack - Senior CMO

HOUSTON , Aug. 3, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti

Live webcast fireside chat on Wednesday, June 21 st at 1:30 PM ET HOUSTON , June 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmac

Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Jenene Thomas - Investor Relations Walter Klemp - Chairman and Chief Executive Offi

Moleculin Biotech (NASDAQ: MBRX ) reported first quarter results for 2023. Moleculin Biotech reported a loss per share of 28 cents.

HOUSTON , May 4, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin

Moleculin Biotech, Inc. (MBRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreem

Moleculin Biotech, Inc. (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).